J.P. Morgan Notebook, Jan. 13: Drug Costs, Gilead, Valeant, Allergan/Actavis, Bristol
This article was originally published in The Pink Sheet Daily
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing talk dominates day two, and companies weigh in on the fallout from failed M&A.
You may also be interested in...
Day three of “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing remains center stage, with AbbVie weighing in on HCV and AstraZeneca’s Soriot predicting cost-competition in oncology. CAR-T continues to advance, with updates from Juno and bluebird.
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.